Andere Sprachen Avidity Biosciences, Inc.

Aktien

A2P5NK

US05370A1088

RNA

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:46:29 10.05.2024			% 5 Tage	% 1. Jan.
26,24 ^USD	-3,19 %		-0,04 %	+192,15 %

08.05.	Avidity Biosciences erhält von der FDA den Status eines Therapiedurchbruchs für die Behandlung von Myotonischer Dystrophie Typ 1	MT
08.05.	Avidity Biosciences, Inc. erhält von der FDA den Status eines Therapiedurchbruchs für Delpacibart Etedesiran (AOC 1001) zur Behandlung von Myotonischer Dystrophie Typ 1	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights	09.05.
Avidity Biosciences to Participate in Upcoming Investor Conference	08.05.
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1	08.05.
Avidity's Lead Program Gets FDA Breakthrough Designation	08.05.
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1	08.05.
Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1	08.05.
Avidity Biosciences : April 2024 Corporate Presentation	30.04.
Avidity Biosciences : (5.7 MB)	29.04.
Avidity Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	23.04.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22.04.
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	04.04.
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	04.04.
Avidity Biosciences to Participate in Upcoming Investor Conferences	27.03.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	21.03.
Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding	19.03.
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	15.03.
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	13.03.
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	05.03.
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial	04.03.
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Avidity Biosciences, Inc.

Aktien

A2P5NK

US05370A1088

RNA

Andere Sprachen

Filter